Products billed under this code include Carvykti.
Payment limit per up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, by effective quarter, 3Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Carvykti | Janssen Biotech, Inc. | 57894-0111-01 | 1 | $594,112.255 |
| Carvykti | Janssen Biotech, Inc. | 57894-0111-02 | 1 | $594,112.255 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $594,112.255 | +$6,134.50 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted September 17, 2026 |
| 3Q26 | $587,977.755 | −$517.053 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted September 15, 2026 |
| 2Q26 | $588,494.808 | +$845.234 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted September 15, 2026 |
| 1Q26 | $587,649.574 | +$21,780.629 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted September 15, 2026 |
| 4Q25 | $565,868.945 | +$12,490.115 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted September 8, 2026 |
| 3Q25 | $553,378.83 | +$209.531 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted March 10, 2026 |
| 2Q25 | $553,169.299 | +$1,850.962 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted March 10, 2026 |
| 1Q25 | $551,318.337 | +$24,194.904 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted December 19, 2025 |
| 4Q24 | $527,123.433 | +$19,436.433 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted June 11, 2025 |
| 3Q24 | $507,687.00 | +$191.449 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted June 11, 2025 |
| 2Q24 | $507,495.551 | +$299.631 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted March 11, 2025 |
| 1Q24 | $507,195.92 | +$10,171.274 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted December 19, 2024 |
| 4Q23 | $497,024.646 | +$4,124.646 | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted October 10, 2024 |
| 3Q23 | $492,900.00 | – | up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells | Ciltacabtagene car-pos t | v1, posted June 5, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
